Mutations in the GIGYF2 (TNRC15) Gene at the PARK11 Locus in Familial Parkinson Disease

American Journal of Human Genetics

Volumn 82, Issue 4, 2008, Pages 822-833

  Lautier, Corinne ^a,b,c   Goldwurm, Stefano ^d   Dürr, Alexandra ^b,c   Giovannone, Barbara ^a   Tsiaras, William G ^a   Pezzoli, Gianni ^d   Brice, Alexis ^b,c   Smith, Robert J ^a  

^a RHODE ISLAND HOSPITAL   (United States)

^b INSERM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d PARKINSON INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ASPARAGINE; ASPARTIC ACID; GLUTAMIC ACID; ISOLEUCINE; SERINE; THREONINE; VALINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CHROMOSOME 2; CONTROLLED STUDY; DISEASE COURSE; EXON; FAMILIAL DISEASE; FEMALE; FRANCE; GENE; GENE DELETION; GENE INSERTION; GENE LOCUS; GENE MUTATION; GENE SEGREGATION; GENE SEQUENCE; GENETIC LINKAGE; GIGYF2 GENE; HUMAN; ITALY; LRKK2 GENE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; ONSET AGE; PARK11 GENE; PARKINSON DISEASE; PENETRANCE; PRIORITY JOURNAL;

ADULT; AGED; CARRIER PROTEINS; CHROMOSOMES, HUMAN, PAIR 2; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARKINSON DISEASE; PEDIGREE;

EID: 41649096247     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajhg.2008.01.015     Document Type: Article

References (55)

1. Lang A.E., and Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 339 (1998) 1044-1053
2. Payami H., and Zareparsi S. Genetic epidemiology of Parkinson's disease. J. Geriatr. Psychiatry Neurol. 11 (1998) 98-106
3. Funayama M., Hasegawa K., Kowa H., Saito M., Tsuji S., and Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann. Neurol. 51 (2002) 296-301
4. Gasser T., Muller-Myhsok B., Wszolek Z.K., Oehlmann R., Calne D.B., Bonifati V., Bereznai B., Fabrizio E., Vieregge P., and Horstmann R.D. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat. Genet. 18 (1998) 262-265
5. Hicks A.A., Petursson H., Jonsson T., Stefansson H., Johannsdottir H.S., Sainz J., Frigge M.L., Kong A., Gulcher J.R., Stefansson K., and Sveinbjornsdottir S. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann. Neurol. 52 (2002) 549-555
6. Liu Y., Fallon L., Lashuel H.A., Liu Z., and Lansbury P.T.J. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111 (2002) 209-218
7. Matsumine H., Saito M., Shimoda-Matsubayashi S., Tanaka H., Ishikawa A., Nakagawa-Hattori Y., Yokochi M., Kobayashi T., Igarashi S., Takano H., et al. Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am. J. Hum. Genet. 60 (1997) 588-596
8. Pankratz N., Nichols W.C., Uniacke S.K., Halter C., Rudolph A., Shults C., Conneally P.M., and Foroud T. Genome screen to identify susceptibility genes for Parkinson disease in a sample without parkin mutations. Am. J. Hum. Genet. 71 (2002) 124-135
9. Polymeropoulos M.H., Higgins J.J., Golbe L.I., Johnson W.G., Ide S.E., Di Iorio G., Sanges G., Stenroos E.S., Pho L.T., Schaffer A.A., et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274 (1996) 1197-1199
10. Schultheis P.J., Hagen T.T., O'Toole K.K., Tachibana A., Burke C.R., McGill D.L., Okunade G.W., and Shull G.E. Characterization of the P5 subfamily of P-type transport ATPases in mice. Biochem. Biophys. Res. Commun. 323 (2004) 731-738
11. Scott W.K., Nance M.A., Watts R.L., Hubble J.P., Koller W.C., Lyons K., Pahwa R., Stern M.B., Kolcher A., Hiner B.C., et al. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 286 (2001) 2239-2244
12. Strauss K.M., Martins L.M., Plun-Favreau H., Marx F.P., Kautzmann S., Berg D., Gasser T., Wszolek Z., Muller T., Bornemann A., et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum. Mol. Genet. 14 (2005) 2099-2111
13. Valente E.M., Bentivoglio A.R., Dixon P.H., Ferraris A., Ialongo T., Frontali M., Albanese A., and Wood N.W. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am. J. Hum. Genet. 68 (2001) 895-900
14. Van Duijn C.M., Dekker M.C., Bonifati V., Galjaard R.J., Houwing-Duistermaat J.J., Snijders P.J., Testers L., Breedveld G.J., Horstink M., Sandkuijl L.A., et al. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am. J. Hum. Genet. 69 (2001) 629-634
15. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
16. Brice A. Genetics of Parkinson's disease: LRRK2 on the rise. Brain 128 (2005) 2760-2762
17. Hedrich K., Kann M., Lanthaler A.J., Dalski A., Eskelson C., Landt O., Schwinger E., Vieregge P., Lang A.E., Breakefield X.O., et al. The importance of gene dosage studies: mutational analysis of the parkin gene in early-onset parkinsonism. Hum. Mol. Genet. 10 (2001) 1649-1656
18. Ibanez P., Bonnet A.M., Debarges B., Lohmann E., Tison F., Pollak P., Agid Y., Durr A., and Brice A. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364 (2004) 1169-1171
19. Ibanez P., De Michele G., Bonifati V., Lohmann E., Thobois S., Pollak P., Agid Y., Heutink P., Durr A., and Brice A. Screening for DJ-1 mutations in early onset autosomal recessive parkinsonism. Neurology 61 (2003) 1429-1431
20. Ibanez P., Lesage S., Lohmann E., Thobois S., De Michele G., Borg M., Agid Y., Durr A., and Brice A. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain 129 (2006) 686-694
21. Lesage S., Lohmann E., Tison F., Durif F., Durr A., and Brice A. Rare heterozygous parkin variants in French early-onset Parkinson's disease patients and controls. J. Med. Genet. 45 (2007) 43-46
22. Lincoln S., Vaughan J., Wood N., Baker M., Adamson J., Gwinn-Hardy K., Lynch T., Hardy J., and Farrer M. Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. Neuroreport 10 (1999) 427-429
23. Paisan-Ruiz C., Lang A.E., Kawarai T., Sato C., Salehi-Rad S., Fisman G.K., Al-Khairallah T., St George-Hyslop P., Singleton A., and Rogaeva E. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology 65 (2005) 696-700
24. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
25. Ramirez A., Heimbach A., Grundemann J., Stiller B., Hampshire D., Cid L.P., Goebel I., Mubaidin A.F., Wriekat A.L., Roeper J., et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38 (2006) 1184-1191
26. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
27. Lesage S., Durr A., Tazir M., Lohmann E., Leutenegger A.L., Janin S., Pollak P., and Brice A. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 354 (2006) 422-423
28. Ozelius L.J., Senthil G., Saunders-Pullman R., Ohmann E., Deligtisch A., Tagliati M., Hunt A.L., Klein C., Henick B., Hailpern S.M., et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354 (2006) 424-425
29. Pankratz N., Nichols W.C., Uniacke S.K., Halter C., Murrell J., Rudolph A., Shults C.W., Conneally P.M., and Foroud T. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum. Mol. Genet. 12 (2003) 2599-2608
30. Pankratz N., Nichols W.C., Uniacke S.K., Halter C., Rudolph A., Shults C., Conneally P.M., and Foroud T. Significant linkage of Parkinson disease to chromosome 2q36-37. Am. J. Hum. Genet. 72 (2003) 1053-1057
31. Prestel J., Sharma M., Leitner P., Zimprich A., Vaughan J.R., Durr A., Bonifati V., De Michele G., Hanagasi H.A., Farrer M., et al. PARK11 is not linked with Parkinson's disease in European families. Eur. J. Hum. Genet. 13 (2005) 193-197
32. Maraganore D.M., de Andrade M., Lesnick T.G., Strain K.J., Farrer M.J., Rocca W.A., Pant P.V., Frazer K.A., Cox D.R., and Ballinger D.G. High-resolution whole-genome association study of Parkinson disease. Am. J. Hum. Genet. 77 (2005) 685-693
33. Risch N., and Merikangas K. The future of genetic studies of complex human diseases. Science 273 (1996) 1516-1517
34. Giovannone B., Lee E., Laviola L., Giorgino F., Cleveland K.A., and Smith R.J. Two novel proteins that are linked to insulin-like growth factor (IGF-I) receptors by the Grb10 adapter and modulate IGF-I signaling. J. Biol. Chem. 278 (2003) 31564-31573
35. Dufresne A.M., and Smith R.J. The adapter protein GRB10 is an endogenous negative regulator of insulin-like growth factor signaling. Endocrinology 146 (2005) 4399-4409
36. Holt L.J., and Siddle K. Grb10 and Grb14: enigmatic regulators of insulin action-and more?. Biochem. J. 388 (2005) 393-406
37. Langlais P., Dong L.Q., Ramos F.J., Hu D., Li Y., Quon M.J., and Liu F. Negative regulation of insulin-stimulated mitogen-activated protein kinase signaling by Grb10. Mol. Endocrinol. 18 (2004) 350-358
38. Laviola L., Giorgino F., Chow J.C., Baquero J.A., Hansen H., Ooi J., Zhu J., Riedel H., and Smith R.J. The adapter protein Grb10 associates preferentially with the insulin receptor as compared with the IGF-I receptor in mouse fibroblasts. J. Clin. Invest. 99 (1997) 830-837
39. Mori K., Giovannone B., and Smith R.J. Distinct Grb10 domain requirements for effects on glucose uptake and insulin signaling. Mol. Cell. Endocrinol. 230 (2005) 39-50
40. Russo V.C., Gluckman P.D., Feldman E.L., and Werther G.A. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr. Rev. 26 (2005) 916-943
41. Schulingkamp R.J., Pagano T.C., Hung D., and Raffa R.B. Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci. Biobehav. Rev. 24 (2000) 855-872
42. Craft S., and Watson G.S. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 3 (2004) 169-178
43. Hu G., Jousilahti P., Bidel S., Antikainen R., and Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30 (2007) 842-847
44. Offen D., Shtaif B., Hadad D., Weizman A., Melamed E., and Gil-Ad I. Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neurosci. Lett. 316 (2001) 129-132
45. Takahashi M., Yamada T., Tooyama I., Moroo I., Kimura H., Yamamoto T., and Okada H. Insulin receptor mRNA in the substantia nigra in Parkinson's disease. Neurosci. Lett. 204 (1996) 201-204
46. Hughes A.J., Daniel S.E., Kilford L., and Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55 (1992) 181-184
47. Hughes A.J., Daniel S.E., and Lees A.J. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 57 (2001) 1497-1499
48. Goldwurm S., Di Fonzo A., Simons E.J., Rohe C.F., Zini M., Canesi M., Tesei S., Zecchinelli A., Antonini A., Mariani C., et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J. Med. Genet. 42 (2005) e65
49. Lesage S., Ibanez P., Lohmann E., Pollak P., Tison F., Tazir M., Leutenegger A.L., Guimaraes J., Bonnet A.M., Agid Y., et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann. Neurol. 58 (2005) 784-787
50. Di Fonzo A., Tassorelli C., De Mari M., Chien H.F., Ferreira J., Rohe C.F., Riboldazzi G., Antonini A., Albani G., Mauro A., et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur. J. Hum. Genet. 14 (2006) 322-331
51. (1987). Fahn S, Elton, RL, and the UPDRS Development Committee (Unified Parkinson's). Disease Rating Scale: Recent Developments in Parkinson's Disease, Volume 2, S. Fahn, C.D. Marsden, D. Calne, and M. Goldstein, eds. (Macmillan Healthcare Information, Florham Park, NJ, USA), 153-163.
52. Gasser T. Genetics of Parkinson's disease. Curr. Opin. Neurol. 18 (2005) 363-369
53. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., and Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA 102 (2005) 16842-16847
54. Freund C., Dotsch V., Nishizawa K., Reinherz E.L., and Wagner G. The GYF domain is a novel structural fold that is involved in lymphoid signaling through proline-rich sequences. Nat. Struct. Biol. 6 (1999) 656-660
55. Kofler M.M., and Freund C. The GYF domain. FEBS J. 273 (2006) 245-256